Found: 155
Select item for more details and to access through your institution.
Medicaid Preferred Drug Lists: Cost Containment and Side Effects.
- Published in:
- PharmacoEconomics, 2006, p. 1, doi. 10.2165/00019053-200624003-00001
- By:
- Publication type:
- Article
Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives?
- Published in:
- PharmacoEconomics, 2006, p. 27, doi. 10.2165/00019053-200624003-00003
- By:
- Publication type:
- Article
Per-patient-per-month Drug Costs in Medicare Part D Protected Classes.
- Published in:
- PharmacoEconomics, 2006, p. 79, doi. 10.2165/00019053-200624003-00007
- By:
- Publication type:
- Article
Preferred Drug Lists and Medicaid Prescriptions.
- Published in:
- PharmacoEconomics, 2006, p. 56
- By:
- Publication type:
- Article
Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods.
- Published in:
- PharmacoEconomics, 2006, p. 41, doi. 10.2165/00019053-200624003-00004
- By:
- Publication type:
- Article
The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003.
- Published in:
- PharmacoEconomics, 2006, p. 5, doi. 10.2165/00019053-200624003-00002
- By:
- Publication type:
- Article
Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence.
- Published in:
- PharmacoEconomics, 2006, p. 65, doi. 10.2165/00019053-200624003-00006
- By:
- Publication type:
- Article
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
- Published in:
- 2006
- By:
- Publication type:
- journal article
Discounting health effects in pharmacoeconomic evaluations: current controversies.
- Published in:
- 2006
- By:
- Publication type:
- commentary
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 12, p. 1221, doi. 10.2165/00019053-200624120-00006
- By:
- Publication type:
- Article
The Authors' Reply.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 12, p. 1181, doi. 10.2165/00019053-200624120-00004
- By:
- Publication type:
- Article
Letter from the commissioner's office at the US FDA.
- Published in:
- 2006
- By:
- Publication type:
- editorial
Do pharmacogenomic tests provide value to policy makers?
- Published in:
- 2006
- By:
- Publication type:
- editorial
Generic health-related quality-of-life assessment in children and adolescents: methodological considerations.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Economic evaluation in the US: what is the missing link?
- Published in:
- 2006
- By:
- Publication type:
- journal article
Economic evaluations in the canadian common drug review.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven?
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 11, p. 1079, doi. 10.2165/00019053-200624110-00005
- By:
- Publication type:
- Article
Information created to evade reality (ICER): things we should not look to for answers.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Using value of information analysis to prioritise health research: some lessons from recent UK experience.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Analysis Sans Frontières: Can We Ever Make Economic Evaluations Generalisable Across Jurisdictions?
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 11, p. 1087, doi. 10.2165/00019053-200624110-00006
- By:
- Publication type:
- Article
Economic evaluation and decision making in the UK.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Utility measurement in healthcare: the things I never got to.
- Published in:
- 2006
- By:
- Publication type:
- journal article
‘Lost in Translation’: Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 11, p. 1101
- By:
- Publication type:
- Article
The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Better analysis for better decisions: facing up to the challenges.
- Published in:
- 2006
- By:
- Publication type:
- editorial
The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Anticoagulation for stroke prevention: high effectiveness, more cost benefit?
- Published in:
- 2006
- By:
- Publication type:
- journal article
Recent developments in decision-analytic modelling for economic evaluation.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Hospitalisation costs of cystic fibrosis.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Disability and quality of life in post-traumatic stress disorder: impact of drug treatment.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Single-inhaler combination therapy for asthma: a review of cost effectiveness.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Should we abandon QALYs as a resource allocation tool?
- Published in:
- 2006
- By:
- Publication type:
- journal article
QALYs: are they helpful to decision makers?
- Published in:
- 2006
- By:
- Publication type:
- journal article
The generalisability of pharmacoeconomic studies: issues and challenges ahead.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
- Published in:
- 2006
- By:
- Publication type:
- journal article
The Authors’ Reply.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
- Published in:
- 2006
- By:
- Publication type:
- commentary
Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 917, doi. 10.2165/00019053-200624090-00008
- By:
- Publication type:
- Article
Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 891, doi. 10.2165/00019053-200624090-00006
- By:
- Publication type:
- Article
Cost-of-Illness Studies: A Review of Current Methods.
- Published in:
- PharmacoEconomics, 2006, v. 24, n. 9, p. 869, doi. 10.2165/00019053-200624090-00005
- By:
- Publication type:
- Article
Using discrete choice experiments within a cost-benefit analysis framework: some considerations.
- Published in:
- 2006
- By:
- Publication type:
- journal article
The value of thinly spread QALYs.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance.
- Published in:
- 2006
- By:
- Publication type:
- journal article